Background The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23.Objectives To analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 drugs who also have a concurrent cancer diagnosis.Methods A retrospective, observational, multicentre study was conducted, enrolling adult patients with moderate-to-severe plaque psoriasis and a personal history of malignancy. The patients were undergoing any anti-IL-23 treatment approved for psoriasis (guselkumab, risankizumab or tildrakizumab).Results In total, 198 patients were enrolled. Among these, 67 (33.8%) had a history of malignancy within the past 5 years, whereas 131 (66.2%) had been diagnosed with cancer prior to that time. During the period of the study, six patients (3.0%) experienced progression or recurrence of their existing neoplasia. Moreover, six (3.0%) were diagnosed with a new neoplasia during the study period, discontinuing biologic treatment in only two cases. A subanalysis investigating the relationship between comorbidities and the incidence of neoplastic progression or recurrence during therapy, as well as the development of a new neoplasia, did not show any statistically significant associations. Similarly, significant associations between previous treatments and increased risk of cancer recurrence, progression or development were not found.Conclusions Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients.The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as anti-IL-23. The aim of our study was to analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 who also have a concurrent cancer diagnosis.
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study / Satolli, F., Gerosa, S., Burlando, M., Cozzani, E.C., Lasagni, C., Manfredini, M., Narcisi, A., Marzano, A.V., Carrera, C.G., Megna, M., Cagni, A., Esposito, M., Fargnoli, M.C., Di Lernia, V., Peccerillo, F., Romanelli, M., Trovato, E., Amerio, P., Carugno, A., Brunasso, G., et al.. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 0307-6938. - 50:9(2025), pp. 1827-1833. [10.1093/ced/llaf184]
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study
Satolli F.;Gerosa S.;Megna M.;Brusasco M.;Feliciani C.
2025-01-01
Abstract
Background The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23.Objectives To analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 drugs who also have a concurrent cancer diagnosis.Methods A retrospective, observational, multicentre study was conducted, enrolling adult patients with moderate-to-severe plaque psoriasis and a personal history of malignancy. The patients were undergoing any anti-IL-23 treatment approved for psoriasis (guselkumab, risankizumab or tildrakizumab).Results In total, 198 patients were enrolled. Among these, 67 (33.8%) had a history of malignancy within the past 5 years, whereas 131 (66.2%) had been diagnosed with cancer prior to that time. During the period of the study, six patients (3.0%) experienced progression or recurrence of their existing neoplasia. Moreover, six (3.0%) were diagnosed with a new neoplasia during the study period, discontinuing biologic treatment in only two cases. A subanalysis investigating the relationship between comorbidities and the incidence of neoplastic progression or recurrence during therapy, as well as the development of a new neoplasia, did not show any statistically significant associations. Similarly, significant associations between previous treatments and increased risk of cancer recurrence, progression or development were not found.Conclusions Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients.The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as anti-IL-23. The aim of our study was to analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 who also have a concurrent cancer diagnosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
